Citadel Advisors’s Orgenesis Inc. Common Stock ORGS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-60
Closed -$1.17K 15711
2022
Q4
$1.17K Buy
+60
New +$1.02K ﹤0.01% 14518
2021
Q4
Sell
-2,130
Closed -$105K 14987
2021
Q3
$105K Buy
+2,130
New +$107K ﹤0.01% 12815

Other funds holding ORGS

Citadel Advisors's ORGS Position: Q1 2023 in Review

Citadel Advisors sold out of Orgenesis Inc. Common Stock (ORGS) in Q1 2023, closing a stake of 1,532 shares — an estimated $29.9K sold.

Citadel Advisors first reported a position in ORGS in Q1 2021 and held it in 5 quarters. The position peaked at $143K in Q2 2021. 20 funds tracked by Wall St. Rank hold ORGS as of Q1 2023.

  • Citadel Advisors reported no remaining Orgenesis Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 1,532 Orgenesis Inc. Common Stock shares in Q1 2023, an estimated $29.9K.
  • Citadel Advisors first reported a position in Orgenesis Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Citadel Advisors's Orgenesis Inc. Common Stock position peaked at $143K in Q2 2021.
  • 20 funds tracked by Wall St. Rank held Orgenesis Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.